Metabolic side effects of the atypical antipsychotic olanzapine in an inpatient population of adults with developmental disabilities

Mental Health Aspects of Developmental Disabilities

Volumn 9, Issue 1, 2006, Pages 18-22

  Leonard, Hasse ^a   Hoheneck, Dagmar ^b  

^a Sonoma Developmental Center ^*  (United States)

^b Sonoma Developmental Center   (United States)

Author keywords

Atypical antipsychotic; Developmental disability; Diabetes; Intellectual disability; Mental retardation; Metabolic side effects; Olanzapine; Psychiatric disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; INTELLECTUAL IMPAIRMENT; LIPID BLOOD LEVEL; MALE; MEDICAL RECORD; MENTAL DEFICIENCY; METABOLIC DISORDER; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 33745959443     PISSN: 10573291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotic induced weight-gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
3. Barnard L, Young AH, Pearson J, et al. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002;16:93-101.
4. Bernstein J. Psychotropic drug induced weight gain: Mechanisms and management. Clin Neuropharmacol 1988;11:3194-3206.
5. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 2002;63:920-930.
6. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatica 1999;40:438-443.
7. Griffiths J, Springuel P. Atypical antipsychotics: Impaired glucose metabolism. Can ADR Newslett 2001;165:943-945.
8. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62:10-14.
9. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
10. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: A retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003;64:1258-1265.
11. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100.
12. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy2002;22:841-852.
13. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-1026.
14. Kretschmar A. New antipsychotics. Nervenheilkunde 2001:3-15.
15. Kretschmar A. Hyperglycemia metabolic effects of schizophrenia-therapy. Nervenheilkunde 2002:2-8.
16. Kozian R. Olanzapine-induced diabetes mellitus. Psychiatr Prax 2002;29:318-320.
17. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296.
18. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-749.
19. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001;21:369-374.
20. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.
21. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
22. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
23. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry 2001;62:273-281.
24. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
25. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychiatry 2003;23:S21-S26.
26. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62:5-12.
27. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizo-affective disorder. Am J Psychiatry 2002;159:255-262.
28. Von Hayek D, Huttl V, Reiss, J, et al. Hyperglycemia and ketoacidosis associated with olanzapine. Nervenarst 1999;70:836-837.
29. Williams H, Clarke R, Bouras N, et al. Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. J Intellect Disability Res 2000;44:164-169.
30. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6.
31. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid level. J Clin Psychiatry 2002;63:856-865.
32. Wirshing DA, Wirshing W, Kysar L, et al. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.